Treatment strategies for juvenile idiopathic arthritis

Bibliography

• Giannini EH, Ruperto N, Ravelli A, Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9
   PubMed Web of Science ®Google Scholar
• Zernikow B, Hechler T. Schmerztherapie bei Kindern und Jugendlichen. Dtsch Arztebl 2008;105(28-9): 511-22
   Google Scholar
• Neidel J, Boehnke M, Küster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum 2002;46(6):1620-8
   PubMedGoogle Scholar
• Beukelman T, Guevara JP, Albert DA. Outcome in the initial treatment of knee monoarthritis in JIA: Results of a decision analysis model. Arthritis Rheum 2007;54(Suppl):S136
   Google Scholar
• Beukelman T, Guevara JP, Albert DA, Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. Clin Exp Rheumatol 2008;26(4):700-3
   PubMedGoogle Scholar
• Zulian F, Martini G, Gobber D, Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford) 2004;43:1288-91
   PubMed Web of Science ®Google Scholar
• Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the USA–USSR double-blind placebo-controlled trial. N Engl J Med 1986;314:1269-76
   PubMed Web of Science ®Google Scholar
• Giannini EH, Brewer EJ Jr, Kuzmina N, Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA–USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. Arthritis Rheum. 1990;33:466-76
   PubMedGoogle Scholar
• Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986;13:118-23
   PubMed Web of Science ®Google Scholar
• Ruperto N, Ravelli A, Castell E, Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006;5:599-605
   Google Scholar
• Giannini EH, Brewer EJ, Kuzmina N, Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA–USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326;(16):1043-9
   PubMedGoogle Scholar
• Ruperto N, Murray KJ, Gerloni V, .; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201
   PubMed Web of Science ®Google Scholar
• Woo P, Southwood TR, Prieur AM, Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2005;43:1849-57
   Google Scholar
• Balis FM, Mirro J Jr, Reaman GH, Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988;6:1882-6
   PubMed Web of Science ®Google Scholar
• Jundt JW, Browne BA, Fiocco GP, A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845-9
   PubMed Web of Science ®Google Scholar
• Horneff G. Wirksamkeit und Verträglichkeit der Therapie mit Methotrexat bei Patienten mit juveniler idiopathischer Arthritis – Analyse aus dem Deutschen Methotrexatregister Tagung der Gesellschaft Kinder- und Jugendrheumatologie, Meerbusch 2007. Z Rheumatol 2007;66:634
   Google Scholar
• Van der Meer A, Wulffraat NM, Prakken BJ, Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007;25(3):480-5
   PubMedGoogle Scholar
• Niehues T, Horneff G, Michels H, Evidenzbasierter Einsatz von Methotrexat bei Kindern mit rheumatischen Erkrankungen. Konsensusstatement der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie Deutschland (AGKJR) und Arbeitsgemeinschaft Pädiatrische Rheumatologie Österreich. Monatsschr Kinderheilkd 2003;151:881-90
   Google Scholar
• Ansell BM, Hall MA, Loftus JK, A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201-3
   PubMedGoogle Scholar
• Van Rossum MA, Fiselier TJ, Franssen MJ, Sulfasalzin in the treatment of juvenile chronic arthritis. A randomized double-blind placebo-controlled multicenter study. Arthritis Rheum 1998;41:808-16
   PubMed Web of Science ®Google Scholar
• Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002; 61:941-2
   PubMed Web of Science ®Google Scholar
• Tsai WC, Chen CJ, Yen JH, Liu HW. Sulphasalazine-induced systemic lupus erythematous in a patient with ankylosing spondylitis. Clin Rheumatol 2002;21(4):339-40
   PubMedGoogle Scholar
• Silverman E, Mouy R, Spiegel L, Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352(16):1655-66
   PubMedGoogle Scholar
• Horneff G, Schmeling H, Biedermann , The German Etanercept Registry for Treatment of Juvenile Idiopathic Arthritis (JIA). Ann Rheum Dis 2004;63:1638-44
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Mingels A, Neudorf U, Ganser G. Juvenile idiopathic arthritis and uveitis: screening and anti-inflammatory therapy. Klin Monatsbl Augenheilkd 2003;220(11):738-53
   PubMedGoogle Scholar
• Manger B. Kommission Pharmakotherapie, Deutsche Gesellschaft fur Rheumatologie. Revised recommendations of the Deutsche Gesellschaft fur Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases. Z Rheumatol 2002;61(6):694-7
   PubMedGoogle Scholar
• Lovell DJ, Reiff A, Jones OY, Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Ilowite NT, Pediatric Rheumatology Collaborative Study Group.Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58(5):1496-504
   PubMedGoogle Scholar
• Horneff G, De Bock F, Foeldvari I, Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25
   Google Scholar
• Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007;28(2):153-6
   PubMedGoogle Scholar
• Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom-Smit LW. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis. 2007;66(5):704-5
   PubMedGoogle Scholar
• Horneff G, Minden K, Foeldvari I, Safety and efficacy of once weekly Etanercept 0.8 mg/kg:Interim analysis of an multicentre 12 week open trial in active juvenile idiopathic arthritis. Ann Rheum Dis 2008;64(Suppl) :268
   Google Scholar
• Horneff G, Ebert A, Fitter S, Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology 2009;48(8):916-9
   PubMedGoogle Scholar
• Horneff G. Einsatz von Biologika bei der juvenilen idiopathischen Arthritis. Konsensusstatement des 7. WÖrlitzer Expertengespräches 2004 für die Arbeitsgemeinschaft Kinder- und Jugendrheumatologie. Monatsschr. Kinderheilkd 2005;153:473-9
   Google Scholar
• Lovell DJ, Ruperto N, Goodman S, .; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359(8):810-20
   PubMed Web of Science ®Google Scholar
• Armbrust W, Kamphuis SS, Wolfs TW, Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004;43:527-9
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R .; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56(9):3096-106
   PubMedGoogle Scholar
• Kay J, Matteson EL, Dasgupta B, Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58(4):964-75
   PubMedGoogle Scholar
• Ilowite N, Porras O, Reiff A, Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28(2):129-37
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, Anakinra in systemic-onset juvenile idiopathic arthritis: result of a multicenter double-blind trial (ANAJIS). Ann Rheum Dis 2008;68(Suppl) :68
   Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-9
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Gianinni EH, Kimura Y, Preliminary evidence for bioactivity of IL-1 trap (Rilonacept), a long acting il-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 2006;54:S325
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, for the Canakinumab in CAPS Study Group. Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. N Engl J Med 2009;360:2416-25
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results of a Tocilizumab sJIA phase III clinical trial. Arthritis Rheum 2006;54:S327
   Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Prieur AM, Assessment of open label co-stimulation blockade with Abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Arthritis Rheum 2006;54:S326
   Google Scholar
• Giannini EH, Ruperto N, Prieur AM, Efficacy and Safety of Abatacept in Children and Adolescents with Active Juvenile Idiopathic Arthritis (JIA): Results of Double-Blind Withdrawal Phase. 2006 Annual Scientific meeting of the American College of Rheumatology, October 16-21, Washington, USA. Arthritis Rheum 2006;54:S482
   PubMedGoogle Scholar
• Kamphuis S, Kuis W, de Jager W, Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005;366(9479):50-6
   PubMedGoogle Scholar
• Kamphuis S, Albani S, Prakken BJ. Heat-shock protein 60 as a tool for novel therapeutic strategies that target the induction of regulatory T cells in human arthritis. Expert Opin Biol Ther 2006;6(6):579-89
   PubMedGoogle Scholar
• Prakken BJ, Samodal R, Le TD, Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA. 2004;101(12):4228-33
   PubMedGoogle Scholar
• Chen G, Li N, Zang Y, Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum 2007;56(2):453-63
   PubMedGoogle Scholar
• Wulffraat NM, van Rooijen EM, Tewarie R, Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Autoimmunity 2008;41(8):632-8
   PubMedGoogle Scholar
• Nerome Y, Imanaka H, Nonaka Y, Takei S. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Mod Rheumatol 2007;17(6):526-8
   PubMedGoogle Scholar